Zolvo is an azole antifungal medicine designed for the treatment of serious systemic and opportunistic fungal infections in patients aged 12 years and older. It is indicated for invasive aspergillosis, as well as candidemia and disseminated candidiasis involving organs such as the skin, abdomen, kidneys, bladder wall, and wound sites. Zolvo is also used in the management of esophageal candidiasis and other severe fungal infections caused by organisms including Scedosporium apiospermum and Fusarium species, such as Fusarium solani. It is particularly valuable in cases where patients are intolerant of or refractory to standard antifungal therapies. By targeting a broad range of resistant fungal pathogens, Zolvo provides effective therapeutic support in life-threatening systemic infections and helps improve clinical outcomes under specialist supervision.